{"id":693,"date":"2022-08-25T19:14:56","date_gmt":"2022-08-25T17:14:56","guid":{"rendered":"http:\/\/eurotau.fr\/?page_id=693"},"modified":"2023-04-01T14:10:16","modified_gmt":"2023-04-01T12:10:16","slug":"list-of-speakers","status":"publish","type":"page","link":"https:\/\/eurotau.fr\/?page_id=693","title":{"rendered":"List of titles of eurotau abstracts"},"content":{"rendered":"\n

List of speakers<\/h2>\n\n\n\n

More to come…<\/p>\n\n\n\n

Frank Bennett<\/strong>, Ionis, USA<\/p>\n\n\n\n

Don Cleveland<\/strong>, UC San Diego, USA<\/p>\n\n\n\n

Ilse Dewachter<\/strong>, Hasselt, Belgium<\/p>\n\n\n\n

ApoE, inflammation and tau in AD: a road towards multi-targeted therapies<\/p>\n\n\n\n

Stephan<\/strong>ie Fowler<\/strong>, London, UK<\/p>\n\n\n\n

Short tau filaments are packaged into extracellular vesicles in AD brain<\/em><\/p>\n\n\n\n

Michel Goedert<\/strong>, Cambridge, UK<\/p>\n\n\n\n

Cryo-EM structures of amyloid filaments from human brains<\/em><\/p>\n\n\n\n

Maud Gratuze<\/strong>, Marseille, France<\/p>\n\n\n\n

TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4<\/em><\/p>\n\n\n\n

J\u00fcrgen G\u00f6tz<\/strong>, Brisbane, Australia<\/p>\n\n\n\n

Tau in Alzheimer’s disease – from pathomechanistic studies to therapeutic ultrasound as a treatment modality<\/em><\/p>\n\n\n\n

Bernard Hanseeuw<\/strong>, Louvain, Belgium<\/p>\n\n\n\n

Specific post-translational modifications of the soluble tau protein distinguish between Alzheimer\u2019s disease, 4R-, and 3R-tauopathies<\/em><\/p>\n\n\n\n

Eckhard Mandelkow<\/strong>, Germany<\/p>\n\n\n\n

Pierre Maquet<\/strong>, Li\u00e8ge, Belgium<\/p>\n\n\n\n

Early brainstem tau relates to cortical excitability in healthy aging<\/em><\/p>\n\n\n\n

Ana Melo de Farias<\/strong>, Brazil & France<\/p>\n\n\n\n

Alzheimer’s risk gene PTK2B effects TAU phosphorylation in human induced neurons<\/em><\/p>\n\n\n\n

Tim Miller,<\/strong> MO, USA<\/p>\n\n\n\n

Leonard Petrucelli<\/strong>, FL, USA<\/p>\n\n\n\n

TMEM106b in FTLD-TDP and PSP<\/em><\/p>\n\n\n\n

Naruhiko Sahara<\/strong>, Inage, Chiba, Japan<\/p>\n\n\n\n

Dissecting mechanisms of tauopathy using in vivo multimodal imaging techniques on tauopathy mouse models<\/em><\/p>\n\n\n\n

Wiep Scheper<\/strong>, Amsterdam, NL<\/p>\n\n\n\n

Understanding Granulovacuolar Degeneration Bodies: A neuron-specific response to tau pathology<\/em><\/p>\n\n\n\n

Maria Grazia Spillantini<\/strong>, Cambridge, UK<\/p>\n\n\n\n

Glial cells in P301S tau transgenic mice show ageing-related features<\/em><\/p>\n\n\n\n

Patrik Verstreken<\/strong>, Leuven, Belgium<\/p>\n\n\n\n

Tau toxicity at the synapse<\/em><\/p>\n\n\n\n

Susanne Wegmann<\/strong>, Berlin, Germany<\/p>\n\n\n\n

Tau aggregation and liquid droplets<\/em><\/p>\n\n\n\n

Claude Wischik<\/strong>, TauRx<\/p>\n\n\n\n

Phase 3 outcomes for tau aggregation inhibitor in Alzheimer\u2019s<\/em><\/p>\n\n\n\n

Title of Eurotau abstracts<\/strong><\/h2>\n\n\n\n
    \n
  • A 3D human co-culture to model neuron-astrocyte interactions in tauopathies<\/li>\n\n\n\n
  • A brain-seeded fibril amplification models the aggregation process of tau in Alzheimer\u2019s disease for drug discovery<\/li>\n\n\n\n
  • A direct CSF-to-blood Tau transport: the tanycytic clearance.<\/li>\n\n\n\n
  • A natural variant of the autophagic receptor NDP52 as a new target for Alzheimer\u2019s Disease<\/li>\n\n\n\n
  • A new mechanism of endogenous Tau aggregation through ApoE\/neuroproteasome complexes<\/li>\n\n\n\n
  • Alzheimer’s risk gene PTK2B affects TAU phosphorylation  in human induced neurons<\/li>\n\n\n\n
  • Analysis of neurofilament light alterations in brain versus blood in TauP301S and 5xFAD mice.<\/li>\n\n\n\n
  • Analysis of the molecular factors driving neuronal pathology in Alzheimer\u2019s Disease using GeneFunnel, a novel gene set enrichment and network analysis tool<\/li>\n\n\n\n
  • Anti-S100B nanobodies as modulators of Tau aggregation<\/li>\n\n\n\n
  • APOE deficiency rescues tau pathology and tau driven neurodegeneration in P301S mouse model<\/li>\n\n\n\n
  • ApoE, inflammation and tau in AD: a road towards multi-targeted therapies.<\/li>\n\n\n\n
  • Chaperone modulation of tau aggregation and condensation<\/li>\n\n\n\n
  • Chaperone regulation of tau liquid-liquid phase separation<\/li>\n\n\n\n
  • Characterizing the interaction between Tau and tubulin using SDL-EPR spectroscopy<\/li>\n\n\n\n
  • CK1\u03b4 activity is required for the accumulation of tau-induced granulovacuolar degeneration bodies<\/li>\n\n\n\n
  • Consequences of a high-fat diet during lactation in a mouse model of tauopathy<\/li>\n\n\n\n
  • Contribution of phosphorylation and aggregation to Tau-mediated toxicity.<\/li>\n\n\n\n
  • Cryo-EM Structures of Amyloid Filaments from Human Brains<\/li>\n\n\n\n
  • Developing the Drosophila wing disc as a model system of Tau internalization and trafficking<\/li>\n\n\n\n
  • Development of an AAV-based model of tauopathy targeting the dentate gyrus to study the role of microglia in the spreading of toxic tau species<\/li>\n\n\n\n
  • Differential implication of large and small extracellular vesicles in tau seeding<\/li>\n\n\n\n
  • Dissecting mechanisms of tauopathy using in vivo multimodal imaging techniques on tauopathy mouse models<\/li>\n\n\n\n
  • Dual Optical Techniques to Study Liquid-Liquid Phase Separation of Tau<\/li>\n\n\n\n
  • Early brainstem tau relates to cortical excitability in healthy aging<\/li>\n\n\n\n
  • Effects of adenosine A2A receptor astrocytic upregulation in the mouse hippocampus<\/li>\n\n\n\n
  • Effects of spermidine on tau-induced mitochondrial dysfunction<\/li>\n\n\n\n
  • Elucidating key components in Alzheimer\u2019s disease progression.<\/li>\n\n\n\n
  • Enriched environment- non-pharmacological alternative to slow down propagation of AD tau pathology and improve cognitive functions<\/li>\n\n\n\n
  • Evaluation of astrocytes morphological changes in tauopathies<\/li>\n\n\n\n
  • Extracellular tau impairs the interaction of tau with microtubules in model neurons: A new cellular model for understanding tauopathies<\/li>\n\n\n\n
  • Free cholesterol regulates neuronal pTau<\/li>\n\n\n\n
  • From early endosomal deficits to severe dendrite collapse: tau pathology in human and mouse neurons<\/li>\n\n\n\n
  • Frontotemporal dementia-associated tau mutations induce altered nucleolar structure before cell death<\/li>\n\n\n\n
  • Glutamatergic drivers of Tau pathology in the human thalamus\u202f<\/li>\n\n\n\n
  • High amount and fast production of tauc3 in ps19 mice<\/li>\n\n\n\n
  • How does insulin resistance increase risk of Alzheimer\u2019s disease?<\/li>\n\n\n\n
  • Human MAPT knock-in mice that harbor familial tauopathy-causing mutations<\/li>\n\n\n\n
  • Human Tau aggregates are permissive to Protein Synthesis Dependent Memory in Drosophila Tauopathy models<\/li>\n\n\n\n
  • Human tau-isoform specific effects in Drosophila CNS<\/li>\n\n\n\n
  • Hydromethylthionine first, rivastigmine second: cognitive effects of single versus combination therapies in tau transgenic mice<\/li>\n\n\n\n
  • Hydromethylthionine induces long-term and sustained decreases in truncated tau in a mouse model of frontotemporal dementia<\/li>\n\n\n\n
  • Identify critical regulators of pre-synaptic tau release<\/li>\n\n\n\n
  • Impact of tau and amyloid-beta lesions on the transcriptome expression in a primate model of Alzheimer\u2019s Disease.<\/li>\n\n\n\n
  • Impact of tau on the ER-mitochondria coupling<\/li>\n\n\n\n
  • Impact of Tau protein on the nuclear envelope and chromatin structure<\/li>\n\n\n\n
  • In vitro aggregation of tau by protein misfolding cyclic amplification<\/li>\n\n\n\n
  • In vitro and in vivo artefacts when analysing tau phosphorylation by Western blot or immunohistochemistry.<\/li>\n\n\n\n
  • In vivo modulation of Tau pathology and neurodegeneration by NLRP3 inflammasome<\/li>\n\n\n\n
  • Interaction between Tau and nuclear transport proteins in Tau protein-associated dementias<\/li>\n\n\n\n
  • Interaction of Alzheimer\u2019s disease genetic risk factors: Characterization of PYK2 AND BIN1 protein-protein interaction<\/li>\n\n\n\n
  • Interaction of tau and A\u03b2 in mouse models of Alzheimer\u2019s disease<\/li>\n\n\n\n
  • Intraneuronal tau aggregation induces the integrated stress response in astrocytes<\/li>\n\n\n\n
  • Investigating BIN1 involvement in tau handling and extracellular vesicle secretion in iPSC-microglia<\/li>\n\n\n\n
  • Investigating role of plumbagin in preventing neurodegenerative diseases via inhibiting the tau phosphorylating kinase MARK4<\/li>\n\n\n\n
  • Investigating the contribution of an intronic variation at the TRIM11\/TRIM17 locus to pathological and clinical heterogeneity in Progressive Supranuclear Palsy<\/li>\n\n\n\n
  • Investigating the endocytic mechanism of pathological tau at the synapse<\/li>\n\n\n\n
  • Investigating the pathological role of Tau associated with Alzheimer’s disease on the nucleolus of neuronal (SH-SY5Y) cells<\/li>\n\n\n\n
  • Investigating the potential of the insulin-sensitizing drug Metformin in ameliorating Tau pathology in cellular and Drosophila models<\/li>\n\n\n\n
  • Investigating the role of ERK, JNK and p38 in the phosphorylation of Thr175 tau associated with traumatic brain injury.<\/li>\n\n\n\n
  • Investigating the synaptic mechanisms of the spread of wild type and P301S 1N4R human tau in in vitro and in vivo models<\/li>\n\n\n\n
  • Isoform-specific siRNAs: A potential therapeutic approach for 4R tauopathies.<\/li>\n\n\n\n
  • Isolation of spontaneously-released brain extracellular vesicles: implications for brain pathology<\/li>\n\n\n\n
  • Lewy body co-pathology contributes to frontal lobe atrophy in Alzheimer\u2019s disease and primary age-related tauopathy (PART)<\/li>\n\n\n\n
  • Live-cell visualization of tau aggregation in human neurons<\/li>\n\n\n\n
  • Local tau reduction rescues pathological phenotypes in a preclinical model of tauopathy<\/li>\n\n\n\n
  • MAPT mutations in Amyotrophic Lateral Sclerosis<\/li>\n\n\n\n
  • MAPT S305 mutations alter neuron and astrocyte function<\/li>\n\n\n\n
  • Mass-spectrometry analysis of a tau hyperphosphorylation model reveals increased stathmin-2 expression as an inducer of microtubule destabilization<\/li>\n\n\n\n
  • Methods to assess the activity of drug candidates on tau aggregation and tau microtubule dynamics<\/li>\n\n\n\n
  • Mical modulates Tau toxicity via cysteine oxidation in vivo<\/li>\n\n\n\n
  • Mutations in tau protein influence aggregation propensity through conformation modulation<\/li>\n\n\n\n
  • NanoBit tau biosensors bring new insights into the molecular events triggering early pathological tau transformation and seeding activity<\/li>\n\n\n\n
  • NanoTarget : An original approach for intracellular delivery of anti-tau single domain antibodies<\/li>\n\n\n\n
  • Neuronal identity defines a-synuclein and tau toxicity<\/li>\n\n\n\n
  • Neuronal vulnerability to tau-mediated toxicity is characterized by a broad spectrum of varying responses<\/li>\n\n\n\n
  • Neuroprotective effects of CB2 cannabinoid receptor antagonists\u2019 treatment in TAU-dependent Frontotemporal Dementia<\/li>\n\n\n\n
  • New Thiazole-Flavone Hybrid Compounds Binding to Tau Protein and With Antitumor Activity Against Glioblastoma<\/li>\n\n\n\n
  • Oligomerization of Tau on Microtubules<\/li>\n\n\n\n
  • Optimization and selection of VHHs targeting Tau nucleation core<\/li>\n\n\n\n
  • Pathogenic Tau reactivates a developmental pruning pathway<\/li>\n\n\n\n
  • Peptide-based inhibitors of Tau aggregation as a potential therapeutic for Alzheimer\u2019s disease and other Tauopathies<\/li>\n\n\n\n
  • Persistent pain causes Tau-mediated hippocampal malfunction and memory deficits<\/li>\n\n\n\n
  • Phase 3 outcomes for tau aggregation inhibitor in Alzheimer\u2019s<\/li>\n\n\n\n
  • Phase separation of a paired-helical filament forming region of tau<\/li>\n\n\n\n
  • Phosphorylated tau is present in the human nucleus incertus of the brain<\/li>\n\n\n\n
  • Physicochemical characterization of cellular Tau accumulations and aggregates using advanced imaging modalities<\/li>\n\n\n\n
  • Presynaptic toxicity of the ad risk gene bin1<\/li>\n\n\n\n
  • Protection against tauopathy is influenced by sex<\/li>\n\n\n\n
  • Proteomic signature of vulnerable neurons in Alzheimer\u2019s disease brains<\/li>\n\n\n\n
  • Purinergic P2Y12 receptor-mediated endocytic accumulation of Tau oligomers with \u03b2-arrestin-1 and follow lysosomal degradation in microglia<\/li>\n\n\n\n
  • Pyk2 and Tau interaction promotes synaptic localization of phospho-Tau 181\/Tau in neurons<\/li>\n\n\n\n
  • Regulation of Tau protein phosphorylation by kinase O-GlcNAcylation and its implication in fibrillar aggregation<\/li>\n\n\n\n
  • Revisiting the involvement of tau in complex neural network remodelling: analysis of the extracellular neuronal activity in organotypic brain slice co-cultures<\/li>\n\n\n\n
  • Screening tyrosine kinases for their involvement in synaptotoxicity induced by tau microtubule-binding region fibrils<\/li>\n\n\n\n
  • Short tau filaments are packaged into extracellular vesicles in AD brain<\/li>\n\n\n\n
  • Silencing of phagocytic receptor MERTK in astrocytes alleviates Tau pathology in rodent models of primary Tauopathies<\/li>\n\n\n\n
  • Specific tau PTMs distinguish AD, 4R &3R tauopathy<\/li>\n\n\n\n
  • Study of the brain-gut axis in a mouse model of Alzheimer\u2019s disease<\/li>\n\n\n\n
  • Study of the interactions between the Alzheimer\u2019s disease genetic risk factors BIN1 and PTK2B<\/li>\n\n\n\n
  • Synaptogyrin-3: A potential target against Tau-induced pre-synaptic defects?<\/li>\n\n\n\n
  • Targeting intracellular tau with intrabodies<\/li>\n\n\n\n
  • Targeting of pathological tau protein in interstitial fluid using anti-PHF6 minibody<\/li>\n\n\n\n
  • Tau aggregation and liquid droplets<\/li>\n\n\n\n
  • Tau biology, tau vaccines and therapeutic ultrasound<\/li>\n\n\n\n
  • Tau secretion is driven by circadian variations of body temperature during the sleep\/wake cycle: implications for tau spreading in Alzheimer’s disease<\/li>\n\n\n\n
  • Tau toxicity at the synapse<\/li>\n\n\n\n
  • Tauopathy-associated PERK variants impair signal transduction and promote tau aggregation<\/li>\n\n\n\n
  • Temperature and Concentration Dependent Alteration in Tau Liquid\u2013liquid Phase Separation through Hyperphosphorylation<\/li>\n\n\n\n
  • The effect of the ApoE Christchurch mutation on AD pathology in a combined amyloid and tau mouse model<\/li>\n\n\n\n
  • The role of human microglia and microglial LRRK2 in tau pathogenesis<\/li>\n\n\n\n
  • The role of tau isoforms in neuronal vulnerability<\/li>\n\n\n\n
  • TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4<\/li>\n\n\n\n
  • Ubiquitination as a modulator of tau aggregation and condensation<\/li>\n\n\n\n
  • Understanding Granulovacuolar Degeneration Bodies: A neuron-specific response to tau pathology<\/li>\n\n\n\n
  • Understanding Granulovacuolar Degeneration Bodies: A neuron-specific response to tau pathology<\/li>\n\n\n\n
  • Validation of an AD brain seed-injection model in hTau mice<\/li>\n\n\n\n
  • Validation of therapeutic siRNAs in hiPSCs-derived neurons, a model of FTDP-17<\/li>\n\n\n\n
  • Visualization of tau pathology using in situ cryo-ET<\/li>\n\n\n\n
  • Zika virus infection of immunocompetent mice leads to a persistent disease associated microglia (DAM)-like phenotype and the pathological phosphorylation of Tau protein.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"

    List of speakers More to come… Frank Bennett, Ionis, USA Don Cleveland, UC San Diego, USA Ilse Dewachter, Hasselt, Belgium ApoE, inflammation and tau in AD: a road towards multi-targeted therapies Stephanie Fowler, London, UK Short tau filaments are packaged into extracellular vesicles in AD brain Michel Goedert, Cambridge, UK Cryo-EM structures of amyloid filaments… Continue reading List of titles of eurotau abstracts<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-693","page","type-page","status-publish","hentry","entry"],"_links":{"self":[{"href":"https:\/\/eurotau.fr\/index.php?rest_route=\/wp\/v2\/pages\/693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eurotau.fr\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/eurotau.fr\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/eurotau.fr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eurotau.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=693"}],"version-history":[{"count":27,"href":"https:\/\/eurotau.fr\/index.php?rest_route=\/wp\/v2\/pages\/693\/revisions"}],"predecessor-version":[{"id":892,"href":"https:\/\/eurotau.fr\/index.php?rest_route=\/wp\/v2\/pages\/693\/revisions\/892"}],"wp:attachment":[{"href":"https:\/\/eurotau.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}